

Betamethasone (0.05%) Cream Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Betamethasone (0.05%) Cream Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

: EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B H360D: May damage the unborn child. Specific target organ toxicity - repeated H372: Causes damage to organs through pro-

exposure, Category 1 longed or repeated exposure.

Long-term (chronic) aquatic hazard, Cat-H410: Very toxic to aquatic life with long lasting

egory 1 effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.

H372 Causes damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.



Betamethasone (0.05%) Cream Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

P264 Wash skin thoroughly after handling.P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Hazardous components which must be listed on the label:

betamethasone

Additional Labelling

EUH208 Contains 4-Chloro-3-methylphenol.

May produce an allergic reaction.

2.3 Other hazards

This substance/mixture contains components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB).

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
4-Chloro-3-methylphenol	59-50-7 200-431-6 604-014-00-3	Acute Tox. 4; H302 Acute Tox. 4; H312 Skin Corr. 1C; H314 Eye Dam. 1; H318 Skin Sens. 1B; H317 STOT SE 3; H335 Aquatic Acute 1; H400 Aquatic Chronic 3; H412 M-Factor (Acute aquatic toxicity): 1	0,1
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Ad- renal gland)	0,064



Betamethasone (0.05%) Cream Formulation

.

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

		Aquatic Chronic 1; H410	
		M-Factor (Chronic aquatic toxicity): 1.000	
PBT and vPvB substance :			
Decamethylcyclopentasiloxane	541-02-6 208-764-9		7

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child.

Causes damage to organs through prolonged or repeated

exposure.

May produce an allergic reaction.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.



Betamethasone (0.05%) Cream Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides Silicon oxides

Formaldehyde

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-



Betamethasone (0.05%) Cream Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

 Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents
Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available



Betamethasone (0.05%) Cream Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	TWA OEL-RL (particulate)	10 mg/m3	ZA OEL
	Further inform		d Limit	
	Further information: Recommended Limit			
		TWA OEL-RL	150 ppm	ZA OEL
		(Vapour + partic-	470 mg/m3	
		ulates)	_	
	Further information: Recommended Limit			
betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm ²	Internal

Occupational exposure limits of decomposition products

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
Formaldehyde	50-00-0	STEL OEL-CL	2 ppm 2,5 mg/m3	ZA OEL	
	Further inforr	Further information: Control Limit			
		TWA OEL-CL	2 ppm	ZA OEL	
			2,5 mg/m3		
	Further inforr	Further information: Control Limit			
		STEL	0,6 ppm	2004/37/EC	
			0,74 mg/m3		
		TWA	0,3 ppm 0,37 mg/m3	2004/37/EC	

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Decamethylcyclopen- tasiloxane	Workers	Inhalation	Long-term systemic effects	97,3 mg/m3
	Workers	Inhalation	Acute systemic effects	62 mg/m3
	Workers	Inhalation	Long-term local ef- fects	24,2 mg/m3
	Consumers	Inhalation	Long-term systemic effects	17,3 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	4,3 mg/m3
	Consumers	Ingestion	Long-term systemic effects	5 mg/kg bw/day
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef-	10 mg/m3



Betamethasone (0.05%) Cream Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

			fects	
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
4-Chloro-3- methylphenol	Workers	Inhalation	Long-term systemic effects	6,289 mg/m3
	Workers	Skin contact	Long-term systemic effects	3,567 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1,551 mg/m3
	Consumers	Skin contact	Long-term systemic effects	1,783 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0,892 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9,33 mg/kg food
Decamethylcyclopentasiloxane	Sewage treatment plant	10 mg/l
	Fresh water sediment	11 mg/kg
	Marine sediment	1,1 mg/kg
	Soil	3,77 mg/kg
	Oral (Secondary Poisoning)	13 mg/kg food
Propylene glycol	Fresh water	260 mg/l
	Marine water	26 mg/l
	Intermittent use/release	183 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg
	Marine sediment	57,2 mg/kg
	Soil	50 mg/kg
4-Chloro-3-methylphenol	Fresh water	0,015 mg/l
	Intermittent use/release	0,015 mg/l
	Marine water	0,002 mg/l
	Sewage treatment plant	2,286 mg/l
	Fresh water sediment	13,981 mg/kg dry weight (d.w.)
	Marine sediment	13,981 mg/kg dry weight (d.w.)
	Soil	6,399 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.)

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,



Betamethasone (0.05%) Cream Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, aprop. gauntlets, disposable

being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Combined particulates, inorganic gas/vapour and organic

vapour type (AB-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : cream Colour : white

Odour : No data available
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : > 93,3 °C

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available



Betamethasone (0.05%) Cream Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

Solubility(ies)

Water solubility : No data available Partition coefficient: n- : Not applicable

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : Not applicable

Particle size : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Vapours may form explosive mixture with air.

Can react with strong oxidizing agents.

Hazardous decomposition products will be formed at elevated

temperatures.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

Thermal decomposition : Formaldehyde

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of:

exposure

Skin contact Ingestion Eye contact

9/22



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

Acute toxicity

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Acute oral toxicity : LD50 (Mouse): 600 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 2,871 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : Acute toxicity estimate: 1.100 mg/kg

Method: Expert judgement

Remarks: Based on harmonised classification in EU regulation

1272/2008, Annex VI

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l

Exposure time: 4 h

Decamethylcyclopentasiloxane:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): 8,67 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : Corrosive after 1 to 4 hours of exposure

betamethasone:

Species : Rabbit

Result : Mild skin irritation

Decamethylcyclopentasiloxane:



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Species : Rabbit

Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

betamethasone:

Species : Rabbit

Result : No eye irritation

Decamethylcyclopentasiloxane:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Assessment : Probability or evidence of low to moderate skin sensitisation

rate in humans

betamethasone:

Exposure routes : Dermal
Species : Guinea pig
Result : Weak sensitizer

Decamethylcyclopentasiloxane:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact Species : Mouse Result : negative



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

Germ cell mutagenicity

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Decamethylcyclopentasiloxane:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat

Application Route: inhalation (vapour) Method: OECD Test Guideline 474

Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with

mammalian liver cells in vivo

Species: Rat

Application Route: Inhalation Method: OECD Test Guideline 486

Result: negative



Betamethasone (0.05%) Cream Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:

4-Chloro-3-methylphenol:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

betamethasone:

Effects on foetal develop-

ment

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 0,05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0,42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

Decamethylcyclopentasiloxane:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: inhalation (vapour)

Method: OPPTS 870.3800

Result: negative

Effects on foetal develop-

ment

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: inhalation (vapour)

Method: OPPTS 870.3800

Result: negative



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

STOT - single exposure

Not classified based on available information.

Components:

4-Chloro-3-methylphenol:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

4-Chloro-3-methylphenol:

Species : Rat

NOAEL : 200 mg/kg LOAEL : 400 mg/kg Application Route : Ingestion Exposure time : 28 Days

betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog

LOAEL : 0,05 mg/kg

Application Route : Oral Exposure time : 28 d

Target Organs : Blood, thymus gland, Adrenal gland



Betamethasone (0.05%) Cream Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

Decamethylcyclopentasiloxane:

Species : Rat

NOAEL : 1.000 mg/kg
LOAEL : > 1.000 mg/kg
Application Route : Ingestion

Method : OECD Test Guideline 408

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

betamethasone:

Inhalation : Target Organs: Adrenal gland

Skin contact : Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

4-Chloro-3-methylphenol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 917 μg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1,5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

: ErC50 (Chlorella pyrenoidosa (aglae)): 15 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC10 (Chlorella pyrenoidosa (aglae)): 2,3 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

: 1

Toxicity to microorganisms : EC50 : 22,86 mg/l

Exposure time: 60 h

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,15 mg/l Exposure time: 28 d

Species: Oncorhynchus mykiss (rainbow trout)

Method: OECD Test Guideline 204

Toxicity to daphnia and other aquatic invertebrates (Chron-

NOEC: 0,32 mg/l Exposure time: 21 d



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

ic toxicity)

Species: Daphnia magna (Water flea)

Method: OECD Test Guideline 211

betamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): > 50 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,052 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

NOEC: 0,07 µg/l Exposure time: 219 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 229

Toxicity to daphnia and other

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 8 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

1.000

Decamethylcyclopentasiloxane:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 16 μg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 2,9 μg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 12

μg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

EC10 (Pseudokirchneriella subcapitata (green algae)): > 12

μg/l



Betamethasone (0.05%) Cream Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

Exposure time: 96 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 2.000 mg/l

Exposure time: 3 h Method: 88/302/EC

Toxicity to fish (Chronic tox-

icity)

NOEC: 14 µg/l Exposure time: 90 d

Species: Oncorhynchus mykiss (rainbow trout)

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 15 µg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

12.2 Persistence and degradability

Components:

4-Chloro-3-methylphenol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 78 % Exposure time: 15 d

Method: OECD Test Guideline 301

Decamethylcyclopentasiloxane:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 0,14 % Exposure time: 28 d

Method: OECD Test Guideline 310

12.3 Bioaccumulative potential

Components:

4-Chloro-3-methylphenol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 5,5 - 13

Partition coefficient: n-

octanol/water

log Pow: 0,477

betamethasone:

Partition coefficient: n-

log Pow: 2,11

octanol/water

Decamethylcyclopentasiloxane:

Bioaccumulation : Species: Pimephales promelas (fathead minnow)

Bioconcentration factor (BCF): 7.060 - 13.300



Betamethasone (0.05%) Cream Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 3.5
 09.04.2021
 1682110-00009
 Date of first issue: 17.05.2017

Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 8,023

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains components considered to

be either persistent, bioaccumulative and toxic (PBT), or very

persistent and very bioaccumulative (vPvB).

Components:

Decamethylcyclopentasiloxane:

Assessment

This substance is considered to be persistent, bioaccumulat-

ing and toxic (PBT).

: This substance is considered to be very persistent and very

bioaccumulating (vPvB).

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : UN 3077 **ADR** : UN 3077



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

 RID
 : UN 3077

 IMDG
 : UN 3077

 IATA
 : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

IATA : Environmentally hazardous substance, solid, n.o.s.

(betamethasone)

14.3 Transport hazard class(es)

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III Labels : 9



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

rid

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined



Betamethasone (0.05%) Cream Formulation



Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed. H312 : Harmful in contact with skin.

H314 : Causes severe skin burns and eye damage.

H317 : May cause an allergic skin reaction.
H318 : Causes serious eye damage.

H330 : Fatal if inhaled.

H335 : May cause respiratory irritation. H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Dam. : Serious eye damage
Repr. : Reproductive toxicity
Skin Corr. : Skin corrosion
Skin Sens. : Skin sensitisation

STOT RE : Specific target organ toxicity - repeated exposure STOT SE : Specific target organ toxicity - single exposure

2004/37/EC : Europe. Directive 2004/37/EC on the protection of workers

from the risks related to exposure to carcinogens or mutagens

at work

ZA OEL : South Africa. Hazardous Chemical Substances Regulations,

Occupational Exposure Limits

2004/37/EC / STEL : Short term exposure limit 2004/37/EC / TWA : Long term exposure limit

ZA OEL / TWA OEL-CL : Long term occupational exposure limits - control limit
ZA OEL / STEL OEL-CL : Short term occupational exposure limits - control limit
ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -



Betamethasone (0.05%) Cream Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 3.5 09.04.2021 1682110-00009 Date of first issue: 17.05.2017

Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA -Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Classification procedure:

Sheet cy, http://echa.europa.eu/

Classification of the mixture:

Repr. 1B H360D Calculation method STOT RE 1 H372 Calculation method Aquatic Chronic 1 H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN